Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: A comparison with the M27-A3 reference method

Medical Mycology

Volumn 48, Issue 5, 2010, Pages 710-719

  Cejudo, M A Trinidad González ^a   Gallego, Auxiliadora González ^a   Lacasa, Emilia Cantón ^b   Aller, Ana Isabel ^a   Romero, Ana ^a   García, Javier Pemán ^b   Quindós Andrés, Guillermo ^c   Martín Mazuelos, Estrella ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antifungal agents; MICs; Susceptibility testing methods; Yeasts

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUTOMATION; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CLINICAL EVALUATION; CLINICAL LABORATORY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGUS ISOLATION; INCUBATION TIME; INTERMETHOD COMPARISON; M27 A3 REFERENCE METHOD; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECTROPHOTOMETRY; TRICHOSPORON ASAHII; VITEK 2 SYSTEM; CANDIDA; DRUG EFFECTS; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MYCOLOGY; PROCEDURES; SPAIN; TRICHOSPORON;

CANDIDA; FILOBASIDIELLA NEOFORMANS; TRICHOSPORON ASAHII;

ANTIFUNGAL AGENTS; AUTOMATION; CANDIDA; CRYPTOCOCCUS NEOFORMANS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOLOGY; SPAIN; TRICHOSPORON;

EID: 77954782550     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903473343     Document Type: Article

References (22)

1. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, third edition: Approved Standard M27-A3. NCCLS, Villanova, PA, USA, 2008.
2. Morace G, Amato G, Bistoni F, et al. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fl uconazole susceptibility testing of Candida species. J Clin Microbiol 2002; 40: 2953-2958.
3. Matar MJ, Ostrosky-Zeichner L, Pretznick VL, et al. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fl uconazole and voriconazole. Antimicrob Agents Chemother 2003; 47: 1647-1651.
4. Espinel-Ingroff A, Pfaller M, Messer SA, et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol 2004; 42: 718-721. (Pubitemid 38222652)
5. Bernal S, Aller AI, Chávez M, et al. Comparison of the Sensititre Yeast One colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species. Chemotherapy 2002; 48: 21-25.
6. Pfaller MA, Jones RN, the Microbiology Resource Committee of the College of American Pathologists. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists (CAP) Microbiology Surveys Program (2001-2003). Arch Pathol Lab Med 2006; 130: 767-778.
7. Martín-Mazuelos E, Gutiérrez MJ, Aller AI, et al. A comparative evaluation of Etest and broth microdilution methods for fl uconazole and itraconazole susceptibility testing of Candida spp. J Antimicrob Chemother 1999; 43: 477-481.
8. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fl uconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J Clin Microbiol 2005; 43: 4535-4540.
9. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fl uconazole-resistant Candida albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291-1294.
10. Aller AI, Claro R, Castro C, et al. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fl uconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005. Chemotherapy 2007; 53: 300-305.
11. Barry AL, Pfaller MA, Brown SD, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457-3459.
12. Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, R. H. Yolken, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 2003; 1693-1711.
13. Ghannoum MA, Ibrahim AS, Yfu, et al. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 30: 2881-2886.
14. Aller AI, Martín-Mazuelos E, Lozano F, et al. Correlation of fl uconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544-1548.
15. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fl uorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518-3521.
16. Pfaller MA, Boyken L, Messer SA, et al. Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determinig amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004; 42: 4977-4979.
17. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species against voriconazole: analysis and proposal for interpretative breakpoints. J Clin Microbiol 2006; 44: 819-826.
18. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fl uconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447.
19. Pfaller MA, Diekema DJ, Procop GW, et al. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fl uconazole against Candida spp. J Clin Microbiol 2006; 45: 796-802.
20. Posteraro B, Martucci R, La Sorda M, et al. Reliability of the VITEK 2 yeast susceptibility test for detection of in vitro resistance to fl uconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata. J Clin Microbiol 2009; 47: 1927-1930.
21. Ostrosky-Zeichner L, Rex JH, Pfaller MA, et al. Rationale for reading fl uconazole MICs at 24 Hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother 2008; 52: 4175-4177.
22. Pfaller MA, Boyken LB, Hollis RJ, et al. Validation of 24-hour fl uconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J Clin Microbiol 2008; 46: 3585-3590.